Cargando…
Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019
This cross-sectional analysis aimed to assess the extent of conflicts of interest among the Japanese government coronavirus disease 2019 (COVID-19) advisory board members and elucidate the accuracy of conflicts of interest (COI) disclosure and management strategies. Using the payment data from all 7...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875957/ https://www.ncbi.nlm.nih.gov/pubmed/36705373 http://dx.doi.org/10.1097/MD.0000000000032776 |
_version_ | 1784878061505740800 |
---|---|
author | Mamada, Hanano Murayama, Anju Ozaki, Akihiko Hashimoto, Takanao Saito, Hiroaki Sawano, Toyoaki Yamashita, Erika Bhandari, Divya Shrestha, Sunil Tanimoto, Tetsuya |
author_facet | Mamada, Hanano Murayama, Anju Ozaki, Akihiko Hashimoto, Takanao Saito, Hiroaki Sawano, Toyoaki Yamashita, Erika Bhandari, Divya Shrestha, Sunil Tanimoto, Tetsuya |
author_sort | Mamada, Hanano |
collection | PubMed |
description | This cross-sectional analysis aimed to assess the extent of conflicts of interest among the Japanese government coronavirus disease 2019 (COVID-19) advisory board members and elucidate the accuracy of conflicts of interest (COI) disclosure and management strategies. Using the payment data from all 79 pharmaceutical companies in Japan between 2017 and 2019 and direct research grants from the Japanese government between 2019 and 2020, we evaluated the extent of financial and non-financial COI among all 20 Japanese government COVID-19 advisory board members. The Ethic Committee of the Medical Governance Research Institute approved this study. Japanese government COVID-19 advisory board members were predominantly male (75.0%) and physicians (50.0%). Between 2019 and 2020, 2 members (10.0%) received a total of $819,244 in government research funding. Another 5 members (25.0%) received $532,127 in payments, including $276,722 in personal fees, from 31 pharmaceutical companies between 2017 and 2019. The average value of the pharmaceutical payments was $9155 (standard deviation: $12,975). Furthermore, neither the Ministry of Health, Labor, and Welfare nor the Japanese Cabinet Secretariat disclosed financial or non-financial COI with industry. Additionally, the government had no policies for managing COI among advisory board members. This study found that the Japanese government COVID-19 advisory board had financial and non-financial COI with pharmaceutical companies and the government. Furthermore, personal communication received as part of this research indicated that there were no rigorous COI management strategies for the COVID-19 advisory board members. Any government must ensure the independence of scientific advisory boards by implementing more rigorous and transparent management strategies that require the declaration and public disclosure of all COI. |
format | Online Article Text |
id | pubmed-9875957 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-98759572023-01-27 Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019 Mamada, Hanano Murayama, Anju Ozaki, Akihiko Hashimoto, Takanao Saito, Hiroaki Sawano, Toyoaki Yamashita, Erika Bhandari, Divya Shrestha, Sunil Tanimoto, Tetsuya Medicine (Baltimore) 6600 This cross-sectional analysis aimed to assess the extent of conflicts of interest among the Japanese government coronavirus disease 2019 (COVID-19) advisory board members and elucidate the accuracy of conflicts of interest (COI) disclosure and management strategies. Using the payment data from all 79 pharmaceutical companies in Japan between 2017 and 2019 and direct research grants from the Japanese government between 2019 and 2020, we evaluated the extent of financial and non-financial COI among all 20 Japanese government COVID-19 advisory board members. The Ethic Committee of the Medical Governance Research Institute approved this study. Japanese government COVID-19 advisory board members were predominantly male (75.0%) and physicians (50.0%). Between 2019 and 2020, 2 members (10.0%) received a total of $819,244 in government research funding. Another 5 members (25.0%) received $532,127 in payments, including $276,722 in personal fees, from 31 pharmaceutical companies between 2017 and 2019. The average value of the pharmaceutical payments was $9155 (standard deviation: $12,975). Furthermore, neither the Ministry of Health, Labor, and Welfare nor the Japanese Cabinet Secretariat disclosed financial or non-financial COI with industry. Additionally, the government had no policies for managing COI among advisory board members. This study found that the Japanese government COVID-19 advisory board had financial and non-financial COI with pharmaceutical companies and the government. Furthermore, personal communication received as part of this research indicated that there were no rigorous COI management strategies for the COVID-19 advisory board members. Any government must ensure the independence of scientific advisory boards by implementing more rigorous and transparent management strategies that require the declaration and public disclosure of all COI. Lippincott Williams & Wilkins 2023-01-27 /pmc/articles/PMC9875957/ /pubmed/36705373 http://dx.doi.org/10.1097/MD.0000000000032776 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | 6600 Mamada, Hanano Murayama, Anju Ozaki, Akihiko Hashimoto, Takanao Saito, Hiroaki Sawano, Toyoaki Yamashita, Erika Bhandari, Divya Shrestha, Sunil Tanimoto, Tetsuya Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019 |
title | Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019 |
title_full | Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019 |
title_fullStr | Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019 |
title_full_unstemmed | Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019 |
title_short | Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019 |
title_sort | observational study of financial and non-financial conflicts of interest among the japanese government advisory board members concerning coronavirus disease 2019 |
topic | 6600 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875957/ https://www.ncbi.nlm.nih.gov/pubmed/36705373 http://dx.doi.org/10.1097/MD.0000000000032776 |
work_keys_str_mv | AT mamadahanano observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019 AT murayamaanju observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019 AT ozakiakihiko observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019 AT hashimototakanao observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019 AT saitohiroaki observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019 AT sawanotoyoaki observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019 AT yamashitaerika observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019 AT bhandaridivya observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019 AT shresthasunil observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019 AT tanimototetsuya observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019 |